Exelixis (EXEL) Interest Coverage Ratio (2010 - 2026)
Exelixis' (EXEL) quarterly Interest Coverage Ratio came in at 128.37 in Q2 2026, down 34.19% year-on-year from 195.05 in Q2 2025, and down 97.93% quarter-over-quarter from 6189.89 in Q1 2026.
Exelixis (EXEL) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Exelixis' Interest Coverage Ratio history runs 17 years deep, the most recent figure standing at 128.37 for Q2 2026.
- On a quarterly basis, Interest Coverage Ratio fell 34.19% year-over-year to 128.37 in Q2 2026; TTM through Apr 2026 was 478.38, a 39.86% decrease from a year earlier, with the FY2026 full-year figure at 9.95, up 41.49% from the prior year.
- Interest Coverage Ratio fell to 128.37 in Q2 2026 per EXEL's latest filing, from 6189.89 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 6189.89 in Q1 2026 and bottomed at 0.98 in Q3 2023.
- The 5-year median for Interest Coverage Ratio is 7.62 (2023), against an average of 593.99.
- Across the five-year window, Interest Coverage Ratio plunged 126.49% in 2023 and soared 326071.19% in 2026, its largest moves.
- Year by year, Interest Coverage Ratio stood at 0.62 in 2022, then jumped by 1324.42% to 7.62 in 2023, then jumped by 1453.7% to 118.43 in 2024, then jumped by 2493.91% to 3071.95 in 2025, then sank by 95.82% to 128.37 in 2026.
- Per Business Quant, the three latest EXEL Interest Coverage Ratio figures stand at 128.37 (Q2 2026), 6189.89 (Q1 2026), and 3071.95 (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | 128.37 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 128.37 |
| Jan 2, 2026 | 6,189.89 |
| Oct 3, 2025 | 3,071.95 |
| Jul 4, 2025 | 313.62 |
| Apr 4, 2025 | 195.05 |
| Jan 3, 2025 | 1.90 |
| Sep 27, 2024 | 118.43 |
| Jun 28, 2024 | 41.31 |
| Mar 29, 2024 | 4.14 |
| Dec 29, 2023 | 7.62 |
| Sep 29, 2023 | -0.98 |
| Jun 30, 2023 | 4.20 |
| Mar 31, 2023 | 2.02 |
| Dec 30, 2022 | -0.62 |
| Sep 30, 2022 | 3.70 |
| Jul 1, 2022 | 7.33 |
| Apr 1, 2022 | 9.84 |
| Dec 31, 2021 | 2.68 |
| Oct 1, 2021 | 406.46 |
| Jul 2, 2021 | 672.17 |